Fennec Pharma Announces Incremental $5M Investment From Petrichor, Original Deal Provided Access to up to $20M of Additional Financing
Fennec Pharma Announces Incremental $5M Investment From Petrichor, Original Deal Provided Access to up to $20M of Additional Financing
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company focused on improving the lives of children with cancer, today announced the third closing of $5 million senior secured promissory notes under the existing agreement with Petrichor. The original investment agreement provided access to up to $20 million of additional financing through December 31, 2023. As part of this closing, Fennec and Petrichor have amended the agreement to provide access to up to $15 million of additional financing through December 31, 2024.
專注於改善癌症兒童生活的商業階段專業製藥公司Fennec Pharmicals Inc.（納斯達克股票代碼：FENC，多倫多證券交易所股票代碼：FRX）今天宣佈，根據與Petrichor的現有協議，第三次發行500萬美元的優先擔保期票。最初的投資協議允許在2023年12月31日之前獲得高達2000萬美元的額外融資。作爲此次收購的一部分，Fennec和Petrichor修改了協議，規定在2024年12月31日之前獲得高達1500萬美元的額外融資。
譯文內容由第三人軟體翻譯。